Equities analysts expect MAXIMUS, Inc. (NYSE:MMS) to post sales of $617.67 million for the current quarter, according to Zacks. Five analysts have issued estimates for MAXIMUS’s earnings. The lowest sales estimate is $611.80 million and the highest is $622.79 million. MAXIMUS posted sales of $622.05 million during the same quarter last year, which suggests a negative year-over-year growth rate of 0.7%. The business is expected to announce its next earnings results on Thursday, May 3rd.
On average, analysts expect that MAXIMUS will report full-year sales of $617.67 million for the current fiscal year, with estimates ranging from $2.48 billion to $2.50 billion. For the next year, analysts forecast that the firm will report sales of $2.61 billion per share, with estimates ranging from $2.59 billion to $2.63 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover MAXIMUS.
MAXIMUS (NYSE:MMS) last posted its quarterly earnings data on Thursday, February 8th. The health services provider reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.01. The business had revenue of $623.10 million during the quarter, compared to analyst estimates of $624.36 million. MAXIMUS had a return on equity of 22.93% and a net margin of 8.99%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company earned $0.71 EPS.
Several equities research analysts have recently issued reports on the company. Canaccord Genuity reaffirmed a “buy” rating on shares of MAXIMUS in a research note on Wednesday, December 27th. Zacks Investment Research raised MAXIMUS from a “sell” rating to a “hold” rating in a research note on Wednesday, January 17th. Finally, Maxim Group reaffirmed a “hold” rating and issued a $69.00 price objective (up from $66.00) on shares of MAXIMUS in a research note on Thursday, February 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $66.60.
Shares of MAXIMUS (MMS) opened at $68.16 on Friday. The stock has a market capitalization of $4,450.00, a P/E ratio of 21.30, a PEG ratio of 2.27 and a beta of 1.21. MAXIMUS has a one year low of $57.12 and a one year high of $72.71. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.01.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 28th. Investors of record on Thursday, February 15th will be paid a dividend of $0.045 per share. This represents a $0.18 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date is Wednesday, February 14th. MAXIMUS’s dividend payout ratio is currently 5.63%.
In related news, General Counsel David Francis sold 3,600 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $64.50, for a total transaction of $232,200.00. Following the completion of the sale, the general counsel now directly owns 10,017 shares of the company’s stock, valued at approximately $646,096.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Russell A. Beliveau sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $71.73, for a total value of $71,730.00. The disclosure for this sale can be found here. Insiders have sold a total of 102,650 shares of company stock valued at $7,034,142 over the last three months. 3.10% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MMS. Stifel Financial Corp increased its holdings in MAXIMUS by 5.2% during the 2nd quarter. Stifel Financial Corp now owns 9,186 shares of the health services provider’s stock worth $576,000 after purchasing an additional 455 shares during the period. Cubist Systematic Strategies LLC increased its holdings in MAXIMUS by 16.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,969 shares of the health services provider’s stock worth $249,000 after purchasing an additional 546 shares during the period. APG Asset Management N.V. purchased a new position in MAXIMUS during the 3rd quarter worth $5,902,000. Fox Run Management L.L.C. increased its holdings in MAXIMUS by 88.5% during the 3rd quarter. Fox Run Management L.L.C. now owns 9,800 shares of the health services provider’s stock worth $632,000 after purchasing an additional 4,600 shares during the period. Finally, First Midwest Bank Trust Division increased its holdings in MAXIMUS by 7.7% during the 3rd quarter. First Midwest Bank Trust Division now owns 21,827 shares of the health services provider’s stock worth $1,408,000 after purchasing an additional 1,562 shares during the period. Institutional investors own 96.76% of the company’s stock.
WARNING: This story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://ledgergazette.com/2018/02/25/617-67-million-in-sales-expected-for-maximus-inc-mms-this-quarter.html.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.